focus -WSS

focus

author：knowledge 2025-10-01 17:21:01 - browse：546

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

hotspot

WSS

White House drug czar issues call for 'recovery

Studies point to risks of excluding people with obesity from drug trials

STAT Summit: Michael J. Fox on progress in Parkinson's research

First Opinion Podcast: Long Covid needs a new approach

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Wikipedia

focus

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Medicare’s new pay boost for primary care is angering specialists

Peter Hotez and the public health issue of online harassment

After decades in use, heart stents finally beat placebo

What does generative AI mean for health care? We asked experts

STAT Summit: Michael J. Fox on progress in Parkinson's research

State Dept. review finds Biden bears some blame for Afghanistan failures

Weight loss drugs should be covered by insurers, AMA says

Guidelines to prevent youth baseball injuries need more muscle

What health policies could hitch a ride on a spending bill?

focus

Senate committee scrutinizes Medicare Advantage brokers

The EU Joint Clinical Assessment needs to live up to its promise

HHS leader on health, climate change and biopharma emissions

Type 2 diabetes prevention programs work at large scale: study

Publishing genetic code of viruses could cause disaster

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

hotspot

focus

knowledge

hotspot